Novel treatment of menopausal hot flushes with an estradiol prodrug
用雌二醇前药治疗更年期潮热的新方法
基本信息
- 批准号:7769500
- 负责人:
- 金额:$ 38.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-03-01 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdverse effectsAffectAftercareAlzheimer&aposs DiseaseAmyotrophic Lateral SclerosisAndropauseAnimal ModelAnimalsAnterior Pituitary GlandAntioxidantsAnxietyAppearanceAreaAttenuatedBiologicalBiological AvailabilityBody TemperatureBrainBrain regionBreastBreast Cancer CellCYP1B1 geneCancer cell lineCaringCell ProliferationCellsCentral Nervous System DiseasesChillsChronicClinicalClonidineComplement 3Conjugated EstrogensDataDevelopmentDoseDropsDrug KineticsDrug or chemical Tissue DistributionEndometrialEnzymesEpithelialEpithelial CellsEstradiolEstrogen ReceptorsEstrogen Replacement TherapyEstrogen ReplacementsEstrogensEstroneEventFaceFatigueFemaleFlushingGene ExpressionGenesGenetic PolymorphismGoalsGoldHeartHeatingHemorrhageHormone replacement therapyHormonesHot flushesHumanHydroquinonesHydroxyl RadicalHypertrophyHypothalamic structureIn VitroKnock-outKnockout MiceLifeLiverMCF7 cellMalignant NeoplasmsMammary Gland ParenchymaMammary NeoplasmsMeasurementMeasuresMediatingMedicalMenopausal SymptomMenopauseMental DepressionMicroscopicModelingMorphineMusNaloxoneNatural regenerationNeuraxisNeuronsNorepinephrineObesityOralOral AdministrationOrganOvariectomyOvaryPalpitationsParentsPerimenopausePeriodicityPharmaceutical PreparationsPhasePhysiologic ThermoregulationPituitary GlandPlacebo EffectPlasmaPlayPostmenopauseProdrugsProgesterone ReceptorsProgestin TherapyProgestinsPublic HealthQuality of lifeRattusReactionReceptor GeneReportingResearchRiskRisk FactorsRoleSeriesSerotoninSerumSkinSkin TemperatureSleep disturbancesSpottingsSweatSweatingSympathetic Nervous SystemSymptomsTailTestingTissuesTumor VolumeUnited StatesUterusVasodilationWeightWithdrawalWomanWorkXenograft procedureabsorptionarmbasebonebrain tissuecigarette smokingdesigndrug discoveryeffective therapyexperienceimprovedin vivoin vivo Modelinhibitor/antagonistinnovationmalignant breast neoplasmmedical attentionmenmiddle agemouse modelneoplastic cellnovelnovel strategiespreventresearch studyreuptakesubcutaneoustissue culture
项目摘要
DESCRIPTION (provided by applicant): Hot flushes pose a significant public health concern world-wide. These perimenopausal symptoms are the primary reason that women seek medical care during the menopausal transition. Hot flushes often negatively impact the quality of life of women because they are associated with sleep disturbances resulting in fatigue, depression, irritability, and forgetfulness, as well as acute physical discomfort and negative effects on work. Current therapies include estrogen or hormone (estrogens + progestins) therapies (ERT and HRT), clonidine, the selective serotonin and/or norepinephrine reuptake inhibitors, and gabapentine. Although ERT or HRT is efficacious in preventing hot flushes, a large number of women cannot or do not want to take estrogen. The efficacy of the other therapies is questionable. Therefore, there is a huge unmet need for a better and safer ERT or HRT. We propose in this application that para-quinol of 17b-estradiol (Q-E2) has the potential to be considered as the optimal ERT. We have shown earlier that para-quinol of estrone (Q-E1) functions as a pro-drug and following its absorption its is converted in selective tissues to E1 via an enzyme catalyzed mechanism involving NADP(H). This conversion is effective in the brain but not in the uterus, breast, or the pituitary gland. Therefore, treatment with quinols of estrogens do not have uterotropic (spotting, bleeding, cancer) and mammotropic (breast cancer) liabilities like any other estrogens, including the frequently used Premarin. Since E2 is the primary and most potent estrogen produced by the human ovary, we propose to consider Q-E2 as a pro-drug for the treatment of perimenopausal symptoms, primarily hot flushes. Our pilot data strongly indicate that Q-E2 blocks hot flush symptoms in a rat model of hot flush, but does not stimulate proliferation in MCF-7 breast cells or the uterus at doses that block the hot flush symptoms. Therefore, Q-E2 seems to be a novel, safe, and optimal ERT for alleviating perimenopausal hot flushes. The proposal describes a series of studies aimed at (i) establishing the optimal dose of Q-E2 following its subcutaneous and oral administration using two rat models of hot flush, (ii) dissecting out the dynamics of Q-E2/E2 conversion in brain areas involved in thermoregulation, (iii) provide evidence that the beneficial actions of Q-E2 are mediated via estrogen receptors, and (iv) confirm the lack of action in the uterus and breast, and the beneficial effects in the bone following its chronic administration to ovariectomized rats. The discovery of a novel and safe ERT would improve the quality of life of hundreds of millions of perimenopausal women world-wide and thus, would have a tremendous impact on public health. Although has not been tested experimentally, Q-E2 might be the choice of therapy of men in the andropause as well. In addition, the pro-drug approach we propose here could provide an impetus for drug discovery of other related or un-related therapies.
描述(由申请人提供):潮热在世界范围内引起了重大的公共卫生问题。这些围绝经期症状是妇女在更年期过渡期间寻求医疗护理的主要原因。潮热往往对妇女的生活质量产生负面影响,因为它与睡眠障碍有关,导致疲劳、抑郁、易怒和健忘,以及严重的身体不适和对工作的负面影响。目前的治疗方法包括雌激素或激素(雌激素+孕激素)治疗(ERT和HRT),可定,选择性血清素和/或去甲肾上腺素再摄取抑制剂,加巴喷丁。虽然ERT或HRT在预防潮热方面是有效的,但很多女性不能或不想服用雌激素。其他疗法的疗效值得怀疑。因此,对更好、更安全的ERT或HRT的需求仍未得到满足。我们在这个应用中提出17b-雌二醇的对醌醇(Q-E2)有可能被认为是最佳ERT。我们之前已经表明,雌酮对醌(Q-E1)作为前药,在其吸收后,通过NADP(H)的酶催化机制在选择性组织中转化为E1。这种转换在大脑中有效,但在子宫、乳房或脑垂体中无效。因此,与其他雌激素(包括常用的普雷马林)一样,用雌激素的醌类药物治疗不具有子宫性(斑点、出血、癌症)和乳房性(乳腺癌)风险。由于E2是人类卵巢产生的主要和最有效的雌激素,我们建议考虑Q-E2作为治疗围绝经期症状的前药,主要是潮热。我们的试点数据强烈表明,Q-E2在大鼠潮热模型中阻断潮热症状,但在阻断潮热症状的剂量下,不会刺激MCF-7乳腺细胞或子宫的增殖。因此,Q-E2似乎是一种新颖、安全、最佳的ERT,可缓解围绝经期潮热。该提议描述了一系列研究,旨在(i)建立Q-E2在皮下和口服给药后的最佳剂量,使用两种热潮红大鼠模型,(ii)解剖Q-E2/E2在涉及体温调节的大脑区域的转化动力学,(iii)提供证据表明Q-E2的有益作用是通过雌激素受体介导的,(iv)确认在子宫和乳房中缺乏作用。以及长期给药对去卵巢大鼠骨骼的有益影响。发现一种新的、安全的ERT将改善全世界数亿围绝经期妇女的生活质量,从而对公共卫生产生巨大影响。虽然没有经过实验测试,但Q-E2也可能是男性更年期的治疗选择。此外,我们在这里提出的前药物方法可以为其他相关或非相关疗法的药物发现提供动力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ISTVAN Jozsef MERCHENTHALER其他文献
ISTVAN Jozsef MERCHENTHALER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ISTVAN Jozsef MERCHENTHALER', 18)}}的其他基金
Brain-selective estrogen therapy for menopausal hot flushes in an advanced translational animal model
在先进的转化动物模型中脑选择性雌激素疗法治疗更年期潮热
- 批准号:
10534761 - 财政年份:2021
- 资助金额:
$ 38.95万 - 项目类别:
Brain-selective estrogen therapy for menopausal hot flushes in an advanced translational animal model
在先进的转化动物模型中脑选择性雌激素疗法治疗更年期潮热
- 批准号:
10327690 - 财政年份:2021
- 资助金额:
$ 38.95万 - 项目类别:
Effect of PACAP on the progression of Parkinson's disease in chronic mouse model
PACAP对慢性小鼠帕金森病进展的影响
- 批准号:
9317792 - 财政年份:2017
- 资助金额:
$ 38.95万 - 项目类别:
Establishment of a primate model for menopausal hot flushes
灵长类动物更年期潮热模型的建立
- 批准号:
9262118 - 财政年份:2016
- 资助金额:
$ 38.95万 - 项目类别:
Effects of brain-selective estradiol on gene expression and female sex behavior
脑选择性雌二醇对基因表达和女性性行为的影响
- 批准号:
8712531 - 财政年份:2013
- 资助金额:
$ 38.95万 - 项目类别:
Effects of brain-selective estradiol on gene expression and female sex behavior
脑选择性雌二醇对基因表达和女性性行为的影响
- 批准号:
8598625 - 财政年份:2013
- 资助金额:
$ 38.95万 - 项目类别:
Hot Flushes and SNPs of the Norepinephrine and Serotonin Transporter Genes
潮热以及去甲肾上腺素和血清素转运蛋白基因的 SNP
- 批准号:
7990619 - 财政年份:2011
- 资助金额:
$ 38.95万 - 项目类别:
Hot Flushes and SNPs of the Norepinephrine and Serotonin Transporter Genes
潮热以及去甲肾上腺素和血清素转运蛋白基因的 SNP
- 批准号:
8245713 - 财政年份:2011
- 资助金额:
$ 38.95万 - 项目类别:
Novel Treatment of menopausal hot flushes with an extradiol prodrug
用额外二醇前药治疗更年期潮热的新方法
- 批准号:
7657235 - 财政年份:2009
- 资助金额:
$ 38.95万 - 项目类别:
Novel Treatment of Menopausal Hot Flushes with an Extradiol Prodrug
用 Extradiol 前药治疗更年期潮热的新方法
- 批准号:
7811694 - 财政年份:2009
- 资助金额:
$ 38.95万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 38.95万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 38.95万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 38.95万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 38.95万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 38.95万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 38.95万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 38.95万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 38.95万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 38.95万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 38.95万 - 项目类别:
Research Grant














{{item.name}}会员




